Trevi Therapeutics
TRVI
13.35
-0.37
-2.70%
Trevi Therapeutics
US · TRVI
#2810 by market cap
Listed 2019
13.35
-0.37
-2.70%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
Clear Street Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $29Market Newswire · 2026/5/8
-
Rating change
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $21Market Newswire · 2026/5/8
-
Rating change
Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23Market Newswire · 2026/7/17
-
Rating change
Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $30Market Newswire · 2026/5/8
-
Rating change
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $24Market Newswire · 2026/7/20
-
Rating change
Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24Market Newswire · 2026/5/8
-
Rating change
JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $28Market Newswire · 2026/8/14
-
Rating change
Trevi Therapeutics (TRVI) Receives a New Rating From B. Riley SecuritiesTipRanks · 2026/8/7
-
Trevi Therapeutics (TRVI.US) will release its financial report after the market close on November 9Market Newswire · 2026/11/4
-
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24Market Newswire · 2026/11/10
-
Rating change
Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $25Market Newswire · 2026/8/7
-
Rating change
BMO Capital Initiates Trevi Therapeutics(TRVI.US) With Buy Rating, Announces Target Price $36Market Newswire · 2026/7/21
-
Rating change
Trevi Therapeutics (TRVI) Receives a Buy From H.C. WainwrightTipRanks · 2026/9/22
-
Rating change
JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $28Market Newswire · 2026/10/23
-
BMO Capital Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $36Market Newswire · 2026/11/10
-
A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $23 to $36Market Newswire · 2026/11/11
-
Rating change
Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23Market Newswire · 2026/8/10
-
Rating change
Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $23Market Newswire · 2026/8/7
-
Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/11/10
-
Rating change
A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $23 to $40Market Newswire · 2026/8/8
-
BMO Capital Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $36Market Newswire · 2026/10/7
-
Rating change
A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $18 to $23Market Newswire · 2026/5/6
-
Rating change
Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/8/7
-
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24Market Newswire · 2026/9/22
-
Rating change
JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24Market Newswire · 2026/5/7
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.
Trevi Therapeutics discussion 0 comments